Evotec SE (EVO)

Market Cap	1.36B
Revenue (ttm)	912.89M
Net Income (ttm)	-182.65M
Shares Out	181.16M
EPS (ttm)	-1.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	67,165
Open	3.780
Previous Close	3.810
Day's Range	3.770 - 3.840
52-Week Range	2.840 - 5.641
Beta	1.10
Analysts	Buy
Price Target	5.90 (+53.65%)
Earnings Date	Aug 13, 2025

About EVO

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic disease...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 4, 2021
• Employees: 4,740
• Stock Exchange: NASDAQ
• Ticker Symbol: EVO
• Website: https://www.evotec.com

Financial Performance

In 2024, Evotec SE's revenue was 796.97 million, an increase of 1.99% compared to the previous year's 781.43 million. Losses were -196.08 million, 133.7% more than in 2023.

Financial numbers in EUR

Analyst Forecast

According to 2 analysts, the average rating for EVO stock is "Buy." The 12-month stock price target is $5.9, which is an increase of 53.65% from the latest price.

Price Target

$5.9

(53.65% upside)

Analyst Consensus: Buy